Spruce Biosciences
@sprucebio.com
Spruce is committed to advancing meaningful therapies for underserved neurological conditions like MPS IIIB (Sanfilippo Syndrome Type B). Our investigational therapy, TA-ERT, is guided by science, empathy, and patient voices to deliver urgently needed outcomes that transform lives.
Spruce Biosciences's Company Logos
Spruce Biosciences's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#00A0D2
Cerulean
0, 160, 210
194, 100, 41
100, 24, 0, 18
#52C3C7
Fountain Blue
82, 195, 199
182, 51, 55
59, 2, 0, 22
#363E3B
Cape Cod
54, 62, 59
158, 7, 23
13, 0, 5, 76
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for rare endocrine disorders. They focus on addressing significant unmet medical needs in this field. Their main product candidate, tildacerfont, is a CRF 1 receptor antagonist that is currently in late-stage trials for adult patients with classic congenital adrenal hyperplasia (CAH).
Additionally, they are conducting a Phase 2 trial for pediatric classic CAH. Spruce aims to revolutionize the treatment of classic CAH by offering a well-tolerated, non-steroidal approach that provides improved disease control and reduced steroid burden for patients. The potential benefits of tildacerfont extend to other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), including a rare form of polycystic ovary syndrome (PCOS).
With their dedicated leadership team and ongoing clinical trials, Spruce Biosciences is committed to making a difference in the lives of patients with rare endocrine disorders
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
